Abstract
BackgroundPhase III studies have demonstrated reduced exacerbation rates with tiotropium Respimat® (tioR) add-on to ICS + LABA in patients with symptomatic asthma (Kerstjens et al. NEJM 2012;367:1198–207). There are currently...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
